A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

159 participants · First posted Nov 13, 2019

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

4,000 participants · First posted Dec 1, 2016

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

50 participants · First posted Dec 30, 2016

mRNA therapy (lipid nanoparticle formulation, Factor VIII deficiency)

human factor VIII

clotting factor VIII

ProQR Therapeutics VIII B.V.

Netherlands

MAGNESIUM FACTOR PTY LTD

Australia

MOTHER SUN PROTECTION FACTOR PTY LTD

Australia

Hemlibra Demonstrates Exercise-Related Bleeding Prevention in Hemophilia A as Pfizer Reports Positive Phase III BAISIS Results

FDA Approves Pfizer's Hympavzi (marstacimab-hncq) for Hemophilia A and B

FDA Approves Pfizer's Hympavzi for Hemophilia A and B